Turkiye Klinikleri Journal of Health Sciences

.: REVIEW
Beslenmenin İnsülin Direnci ve İnflamasyon Üzerine Etkisi
Efect of Nutrition on Insulin Resistance and Inflammation
Gülin ÖZTÜRK ÖZKANa
aBeslenme ve Diyetetik Bölümü, İstanbul Medeniyet Üniversitesi Sağlık Bilimleri Fakültesi, İstanbul, TÜRKİYE
Turkiye Klinikleri J Health Sci. 2019;4(3):358-68
doi: 10.5336/healthsci.2018-62977
Article Language: TR
Full Text
ÖZET
 İnsülin direnci, periferal dokuların insülin hareketine cevabının azalması olarak tanımlanmaktadır. Dünya'da obezite ve insülin direnci prevelansı önemli ölçüde artmaktadır. Bu durumun oluşumunda beslenmenin büyük rolü bulunmaktadır. İnsülin direnci, Tip 2 diyabet gelişimi için major risk faktörüdür. İnsülin direnci, çoğu hastalığın gelişimini de kolaylaştırmaktadır. Bunlar arasında Tip 2 diyabet, kalp ve damar hastalıklar, polikistik over sendromu, alkolik olmayan karaciğer hastalığı yer almaktadır. İnflamasyonun, insülin direnci oluşum sürecinde etkili olduğu düşünülmektedir. Adipoz dokudan insülin direnci gelişiminde etkili olabilen çeşitli faktörler salınmaktadır. Besin ögeler, bu inflamatuar göstergeler üzerine etki gösterebilmektedir. Besin ögeleri ve sitokin üretimi arasındaki ilişki yapılan araştırmalar ile gün yüzüne çıkmaya başlamıştır. Beslenme, inflamasyonda kritik rol oynamakta ve insülin direnci gelişim mekanizmalarını etkilemektedir. Bu makaledeki amaç; insülin direnci oluşumunda rol oynayan inflamasyon ile beslenme arasındaki ilişkiyi ortaya koymak ve insülin direnci gelişimine karşı geliştirilecek beslenme strajilerine katkı sağlamaktır. Diyetin yağ içeriğinin düşük olmasının, n-3 yağ asitleri, yüksek posa, A vitamini, C vitamini, D vitamini, E vitamini ve çinko tüketiminin anti-inflamatuar etkilerinin olduğu görülmüştür. İnsülin direncinde diyet tedavisi vücut ağırlığının azaltılması üzerine odaklanmalıdır. Protein ve yağ yeterli miktarda verilmelidir. Diyetin doymuş yağ içeriği azaltılmalı, vitamin mineral ve posa içeriği artırılmalıdır. Sonuç olarak, beslenme insülin direnci ve inflamasyonun önlenmesinde önemli rol oynamaktadır. Bu nedenle, söz konusu durumlara maruz kalan bireylerin yeterli ve dengeli beslenmeyi alışkanlık haline getirmeleri gerekmektedir.

Anahtar Kelimeler: İnsülin direnci; inflamasyon; beslenme
ABSTRACT
 Insulin resistance is defined as a reduction in response to insulin action by peripheral tissues. The prevalence of obesity and insulin resistance in the world is significantly increasing. Nutrition plays a major role in the formation of this condition. Insulin resistance is a major risk factor for the development of Type 2 diabetes. Insulin resistance also facilitates the development of many diseases. These include Type 2 diabetes, cardiovascular diseases, polycystic ovary syndrome, non-alcoholic liver disease. Inflammation is thought to be effective in the process of insulin resistance formation. Various factors that can be effective in the development of insulin resistance from adipose tissue are released. Nutrients may have an effect on these inflammatory indicators. The relationship between nutrients and cytokine production started to be revealed by researches. Nutrition plays a critical role in inflammation and affects the mechanisms of insulin resistance development. The purpose of this article is; to determine the relationship between nutrition and inflammation which is involved in the formation of insulin resistance and to contribute to the development of nutrition strategies against insulin resistance. The low fat content of the diet was found to have anti-inflammatory effects of n-3 fatty acids, high fiber, vitamin A, vitamin C, vitamin D, vitamin E and zinc consumption. Dietary therapy for insulin resistance should focus on reducing body weight. Protein and fat should be given in sufficient quantities. The saturated fat content of the diet should be reduced, the vitamin mineral and pulp content should be increased. As a result, nutrition plays an important role in the prevention of insulin resistance and inflammation. For this reason, it is necessary for the individuals who are exposed to these situations to make a habit of eating adequate and balanced diet.

Keywords: Insulin resistance; inflammation; nutrition
REFERENCES:
  1. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-30. [Crossref]  [PubMed]  [PMC] 
  2. McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007;157 Suppl 1:S51-6. [Crossref]  [PubMed] 
  3. Melmer A, Kempf P, Laimer M. The role of physical exercise in obesity and diabetes. Praxis (Bern 1994). 2018;107(17-18):971-6. [Crossref]  [PubMed] 
  4. Gulcu F, Parmaksiz A, Kidir M, Gursu MF. [Metabolik syndrome]. Firat Saglik Hizmetleri Dergisi. 2006;1(3):23-32.
  5. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917-25. [Crossref]  [PubMed]  [PMC] 
  6. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112(12):1785-8. [Crossref]  [PubMed]  [PMC] 
  7. Oliveira AG, Araujo TG, Carvalho BM, Rocha GZ, Santos A, Saad MJA. The role of hepatocyte growth factor (HGF) in insulin resistance and diabetes. Front Endocrinol (Lausanne). 2018;9:503. [Crossref]  [PubMed]  [PMC] 
  8. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz). 2013;61(2):119-25. [Crossref]  [PubMed] 
  9. Sankaranarayanan S, Untoro J, Erhardt J, Gross R, Rosales FJ. Daily iron alone but not in combination with multimicronutrients increases plasma ferritin concentrations in indonesian infants with inflammation. J Nutr. 2004;134(8):1916-22. [Crossref]  [PubMed] 
  10. Keane KN, Cruzat VF, Carlessi R, de Bittencourt PI Jr, Newsholme P. Molecular events linking oxidative stress and inflammation to insulin resistance and beta-cell dysfunction. Oxid Med Cell Longev. 2015;2015:181643. [Crossref]  [PubMed]  [PMC] 
  11. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2003;78(6):1135-40. [Crossref]  [PubMed] 
  12. Oishi JC, Castro CA, Silva KA, Fabricio V, Carnio EC, Phillips SA, et al. Endothelial dysfunction and inflammation precedes elevations in blood pressure induced by a high-fat diet. Arq Bras Cardiol. 2018;110(6):558-67. [Crossref]  [PubMed]  [PMC] 
  13. Lepretti M, Martucciello S, Burgos Aceves MA, Putti R, Lionetti L. Omega-3 fatty acids and insulin resistance: focus on the regulation of mitochondria and endoplasmic reticulum stress. Nutrients. 2018;10(3). [Crossref]  [PubMed]  [PMC] 
  14. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 Suppl):1505S-19S. [Crossref] 
  15. Li CC, Yang HT, Hou YC, Chiu YS, Chiu WC. Dietary fish oil reduces systemic inflammation and ameliorates sepsis-induced liver injury by up-regulating the peroxisome proliferator-activated receptor gamma-mediated pathway in septic mice. J Nutr Biochem. 2014;25(1):19-25. [Crossref] 
  16. Hansen NW, Sams A. The microbiotic highway to health-new perspective on food structure, gut microbiota, and host inflammation. Nutrients. 2018;10(11). [Crossref]  [PubMed]  [PMC] 
  17. Alves BC, Silva TR, Spritzer PM. Sedentary lifestyle and high-carbohydrate intake are associated with low-grade chronic inflammation in post-menopause: a cross-sectional study. Rev Bras Ginecol Obstet. 2016;38(7):317-24. [Crossref]  [PubMed] 
  18. Minihane AM, Vinoy S, Russell WR, Baka A, Roche HM, Tuohy KM, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 2015;114(7):999-1012. [Crossref]  [PubMed]  [PMC] 
  19. Bayliak MM, Abrat OB, Storey JM, Storey KB, Lushchak VI. Interplay between diet-induced obesity and oxidative stress: comparison between drosophila and mammals. Comp Biochem Physiol A Mol Integr Physiol. 2018;228:18-28. [Crossref]  [PubMed] 
  20. Draganidis D, Karagounis LG, Athanailidis I, Chatzinikolaou A, Jamurtas AZ, Fatouros IG. Inflammaging and skeletal muscle: can protein intake make a difference? J Nutr. 2016;146(10):1940-52. [Crossref]  [PubMed] 
  21. Ahmadi-Kani Golzar F, Fathi R, Mahjoub S. High fat diet leads to adiposity and adipose tissue inflammation: the effect of whey protein supplementation and aerobic exercise training. Appl Physiol Nutr Metab. 2018 Aug 14. Doi: 10.1139/apnm-2018-0307. [Epub ahead of print]. [Crossref]  [PubMed] 
  22. Zhang Z, Zhang R, Qin ZZ, Chen JP, Xu JY, Qin LQ. Effects of chronic whey protein supplementation on atherosclerosis in ApoE(-/-) mice. J Nutr Sci Vitaminol (Tokyo). 2018;64(2):143-50. [Crossref]  [PubMed] 
  23. Lan A, Andriamihaja M, Blouin JM, Liu X, Descatoire V, Desclee de Maredsous C, et al. High-protein diet differently modifies intestinal goblet cell characteristics and mucosal cytokine expression in ileum and colon. J Nutr Biochem. 2015;26(1):91-8. [Crossref]  [PubMed] 
  24. Tak KH, Ahn E, Kim E. Increase in dietary protein content exacerbates colonic inflammation and tumorigenesis in azoxymethane-induced mouse colon carcinogenesis. Nutr Res Pract. 2017;11(4):281-9. [Crossref]  [PubMed]  [PMC] 
  25. Syauqy A, Hsu CY, Rau HH, Chao JC. Association of dietary patterns with components of metabolic syndrome and inflammation among middle-aged and older adults with metabolic syndrome in Taiwan. Nutrients. 2018;10(2). [Crossref]  [PubMed]  [PMC] 
  26. Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Stanek EJ 3rd, et al. Association between dietary fiber and serum C-reactive protein. Am J Clin Nutr. 2006;83(4):760-6. [Crossref]  [PubMed]  [PMC] 
  27. Villamor E, Fawzi WW. Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes. Clin Microbiol Rev. 2005;18(3):446-64. [Crossref]  [PubMed]  [PMC] 
  28. Spinas E, Saggini A, Kritas SK, Cerulli G, Caraffa A, Antinolfi P, et al. Can vitamin a mediate immunity and inflammation? J Biol Regul Homeost Agents. 2015;29(1):1-6.
  29. She C, Shang F, Zhou K, Liu N. Serum carotenoids and risks of diabetes and diabetic retinopathy in a Chinese population sample. Curr Mol Med. 2017;17(4):287-97. [Crossref]  [PubMed] 
  30. Iqbal S, Naseem I. Role of vitamin A in type 2 diabetes mellitus biology: effects of intervention therapy in a deficient state. Nutrition. 2015;31(7-8):901-7. [Crossref]  [PubMed] 
  31. Castellani ML, Shaik-Dasthagirisaheb YB, Tripodi D, Anogeianaki A, Felaco P, Toniato E, et al. Interrelationship between vitamins and cytokines in immunity. J Biol Regul Homeost Agents. 2010;24(4):385-90.
  32. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab. 2004;89(11):5592-6. [Crossref] 
  33. Yang Y, Yuan Y, Tao Y, Wang W. Effects of vitamin A deficiency on mucosal immunity and response to intestinal infection in rats. Nutrition. 2011;27(2):227-32. [Crossref]  [PubMed] 
  34. Klassert TE, Hanisch A, Brauer J, Klaile E, Heyl KA, Mansour MK, et al. Modulatory role of vitamin A on the Candida albicans-induced immune response in human monocytes. Med Microbiol Immunol. 2014;203(6):415-24. [Crossref]  [PubMed]  [PMC] 
  35. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. J Clin Med. 2018;7(9). [Crossref]  [PubMed]  [PMC] 
  36. Bowie AG, O'Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000;165(12):7180-8. [Crossref]  [PubMed] 
  37. Garcia-Diaz DF, Lopez-Legarrea P, Quintero P, Martinez JA. Vitamin C in the treatment and/or prevention of obesity. J Nutr Sci Vitaminol (Tokyo). 2014;60(6):367-79. [Crossref]  [PubMed] 
  38. Goncalves D, Lima C, Ferreira P, Costa P, Costa A, Figueiredo W, et al. Orange juice as dietary source of antioxidants for patients with hepatitis C under antiviral therapy. Food Nutr Res. 2017;61(1):1296675. [Crossref]  [PMC] 
  39. Ellulu MS, Rahmat A, Patimah I, Khaza'ai H, Abed Y. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial. Drug Des Devel Ther. 2015;9:3405-12. [Crossref]  [PubMed]  [PMC] 
  40. Das B, Maity PC, Sil AK. Vitamin C forestalls cigarette smoke induced NF-kappaB activation in alveolar epithelial cells. Toxicol Lett. 2013;220(1):76-81. [Crossref]  [PubMed] 
  41. Sassi F, Tamone C, D'Amelio P. Vitamin D: nutrient, hormone, and immunomodulator. Nutrients. 2018;10(11). [Crossref]  [PMC] 
  42. Mazzone G, Morisco C, Lembo V, D'Argenio G, D'Armiento M, Rossi A, et al. Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats. United European Gastroenterol J. 2018;6(7):1056-64. [Crossref]  [PubMed]  [PMC] 
  43. Wei Z, Yoshihara E, He N, Hah N, Fan W, Pinto AFM, et al. Vitamin D switches BAF complexes to protect beta cells. Cell. 2018;173(5):1135-49.e15. [Crossref]  [PubMed]  [PMC] 
  44. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol. 2003;134(1-2): 128-32. [Crossref] 
  45. Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics. 2004;18(2): 141-51. [Crossref]  [PubMed] 
  46. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients. 2015;7(4):3011-21. [Crossref]  [PubMed]  [PMC] 
  47. Yu Y, Tian L, Xiao Y, Huang G, Zhang M. Effect of vitamin D supplementation on some inflammatory biomarkers in type 2 diabetes mellitus subjects: a systematic review and meta-analysis of randomized controlled trials. Ann Nutr Metab. 2018;73(1):62-73. [Crossref]  [PubMed] 
  48. Choi KM, Lee KW, Kim SG, Kim NH, Park CG, Seo HS, et al. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus. J Clin Endocrinol Metab. 2005;90(1):175-80. [Crossref]  [PubMed] 
  49. Jamilian M, Shojaei A, Samimi M, Afshar Ebrahimi F, Aghadavod E, Karamali M, et al. The effects of omega-3 and vitamin E co-supplementation on parameters of mental health and gene expression related to insulin and inflammation in subjects with polycystic ovary syndrome. J Affect Disord. 2018;229:41-7. [Crossref]  [PubMed] 
  50. Leichtle A, Teupser D, Thiery J. Alpha-tocopherol distribution in lipoproteins and anti-inflammatory effects differ between CHD-patients and healthy subjects. J Am Coll Nutr. 2006;25(5):420-8. [Crossref]  [PubMed] 
  51. Ibs KH, Rink L. Zinc-altered immune function. J Nutr. 2003;133(5 Suppl 1):1452S-6S. [Crossref]  [PubMed] 
  52. Liuzzi JP, Lichten LA, Rivera S, Blanchard RK, Aydemir TB, Knutson MD, et al. Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A. 2005;102(19):6843-8. [Crossref]  [PMC] 
  53. Sandstead HH, Prasad AS, Penland JG, Beck FW, Kaplan J, Egger NG, et al. Zinc deficiency in Mexican American children: influence of zinc and other micronutrients on T cells, cytokines, and antiinflammatory plasma proteins. Am J Clin Nutr. 2008;88(4):1067-73. [Crossref]  [PubMed] 
  54. Vasto S, Mocchegiani E, Malavolta M, Cuppari I, Listi F, Nuzzo D, et al. Zinc and inflammatory/immune response in aging. Ann N Y Acad Sci. 2007;1100:111-22. [Crossref]  [PubMed] 
  55. Garcia OP, Ronquillo D, del Carmen Caama-o M, Martinez G, Camacho M, Lopez V, et al. Zinc, iron and vitamins A, C and e are associated with obesity, inflammation, lipid profile and insulin resistance in Mexican school-aged children. Nutrients. 2013;5(12): 5012-30. [Crossref]  [PubMed]  [PMC] 
  56. Soinio M, Marniemi J, Laakso M, Pyorala K, Lehto S, Ronnemaa T. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care. 2007;30(3): 523-8. [Crossref]  [PubMed] 
  57. Bailey CJ. Treating insulin resistance: future prospects. Diab Vasc Dis Res. 2007;4(1):20-31. [Crossref]  [PubMed] 
  58. Miao X, Sun W, Fu Y, Miao L, Cai L. Zinc homeostasis in the metabolic syndrome and diabetes. Front Med. 2013;7(1):31-52. [Crossref]  [PubMed] 
  59. Bao S, Knoell DL. Zinc modulates cytokine-induced lung epithelial cell barrier permeability. Am J Physiol Lung Cell Mol Physiol. 2006;291(6):L1132-41. [Crossref]  [PubMed] 
  60. Jung S, Kim MK, Choi BY. The relationship between zinc status and inflammatory marker levels in rural korean adults aged 40 and older. PLoS One. 2015;10(6):e0130016. [Crossref]  [PubMed]  [PMC] 
  61. Shen H, Oesterling E, Stromberg A, Toborek M, MacDonald R, Hennig B. Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling. J Am Coll Nutr. 2008;27(5):577-87. [Crossref]  [PubMed] 
  62. Bonaventura P, Benedetti G, Albarede F, Miossec P. Zinc and its role in immunity and inflammation. Autoimmun Rev. 2015;14(4): 277-85. [Crossref]  [PubMed] 
  63. Afshar Ebrahimi F, Foroozanfard F, Aghadavod E, Bahmani F, Asemi Z. The effects of magnesium and zinc co-supplementation on biomarkers of inflammation and oxidative stress, and gene expression related to inflammation in polycystic ovary syndrome: a randomized controlled clinical trial. Biol Trace Elem Res. 2018;184(2):300-7. [Crossref]  [PubMed] 
  64. Kim J, Ahn J. Effect of zinc supplementation on inflammatory markers and adipokines in young obese women. Biol Trace Elem Res. 2014;157(2):101-6. [Crossref] 
  65. Gammoh NZ, Rink L. Zinc in infection and inflammation. Nutrients. 2017;9(6). [Crossref]  [PubMed]  [PMC] 
  66. von Bulow V, Dubben S, Engelhardt G, Hebel S, Plumakers B, Heine H, et al. Zinc-dependent suppression of TNF-alpha production is mediated by protein kinase A-induced inhibition of Raf-1, I kappa B kinase beta, and NF-kappa B. J Immunol. 2007;179(6):4180-6. [Crossref]  [PubMed] 
  67. Drake TC, Rudser KD, Seaquist ER, Saeed A. Chromium infusion in hospitalized patients with severe insulin resistance: a retrospective analysis. Endocr Pract. 2012;18(3):394-8. [Crossref]  [PubMed] 
  68. Hao C, Hao J, Wang W, Han Z, Li G, Zhang L, et al. Insulin sensitizing effects of oligomannuronate-chromium (III) complexes in C2C12 skeletal muscle cells. PLoS One. 2011;6(9): e24598. [Crossref]  [PMC] 
  69. Ali A, Ma Y, Reynolds J, Wise JP Sr, Inzucchi SE, Katz DL. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract. 2011; 17(1):16-25. [Crossref]  [PMC] 
  70. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001;414(6865):821-7. [Crossref]  [PubMed] 
  71. Chen M, Sun JP, Liu J, Yu X. [Research progress of several protein tyrosine phosphatases in diabetes]. Sheng Li Xue Bao. 2010;62(2):179-89.
  72. Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome--the optimal diet. Br J Nutr. 2000;83 Suppl 1:S143-8. [Crossref]  [PubMed] 
  73. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes. 2016;7(19):483-514. [Crossref]  [PubMed]  [PMC] 
  74. Sousa RML, Ribeiro NLX, Pinto BAS, Sanches JR, da Silva MU, Coelho CFF, et al. Long-term high-protein diet intake reverts weight gain and attenuates metabolic dysfunction on high-sucrose-fed adult rats. Nutr Metab (Lond). 2018;15:53. [Crossref]  [PubMed]  [PMC] 
  75. Isharwal S, Misra A, Wasir JS, Nigam P. Diet & insulin resistance: a review & Asian Indian perspective. Indian J Med Res. 2009;129(5): 485-99.
  76. Haag M, Dippenaar NG. Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. Med Sci Monit. 2005;11(12):RA359-67.
  77. Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, et al. Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resis-tance despite obesity. Diabetes. 2015;64(6): 2116-28. [Crossref]  [PubMed] 
  78. Bessesen DH. The role of carbohydrates in insulin resistance. J Nutr. 2001;131(10):2782S-6S. [Crossref]  [PubMed] 
  79. Visuthranukul C, Sirimongkol P, Prachansuwan A, Pruksananonda C, Chomtho S. Low-glycemic index diet may improve insulin sensitivity in obese children. Pediatr Res. 2015;78(5):567-73. [Crossref]  [PubMed] 
  80. Tzotzas T, Papadopoulou FG, Tziomalos K, Karras S, Gastaris K, Perros P, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab. 2010;95(9):4251-7. [Crossref]  [PubMed] 
  81. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al; American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008;31 Suppl 1:S61-78. [Crossref]  [PubMed] 
  82. dos Santos LC, de Padua Cintra I, Fisberg M, Martini LA. Calcium intake and its relationship with adiposity and insulin resistance in post-pubertal adolescents. J Hum Nutr Diet. 2008;21(2):109-16. [Crossref]  [PubMed] 
  83. Norouzi S, Adulcikas J, Sohal SS, Myers S. Zinc transporters and insulin resistance: therapeutic implications for type 2 diabetes and metabolic disease. J Biomed Sci. 2017;24(1):87. [Crossref]  [PubMed]  [PMC] 
  84. Sekgala MD, Mchiza ZJ, Parker WA, Monyeki KD. Dietary fiber intake and metabolic syndrome risk factors among Young South African adults. Nutrients. 2018;10(4). [Crossref]  [PubMed]  [PMC] 
  85. Ogihara T, Asano T, Ando K, Sakoda H, Anai M, Shojima N, et al. High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension. 2002;40(1):83-9. [Crossref]  [PubMed] 
  86. Schrieks IC, Heil AL, Hendriks HF, Mukamal KJ, Beulens JW. The effect of alcohol consumption on insulin sensitivity and glycemic status: a systematic review and meta-analysis of intervention studies. Diabetes Care. 2015;38(4):723-32.
  87. de Las Heras N, Klett-Mingo M, Ballesteros S, Martin-Fernandez B, Escribano O, Blanco-Rivero J, et al. Chronic exercise improves mitochondrial function and insulin sensitivity in brown adipose tissue. Front Physiol. 2018;9:1122. [Crossref]  [PubMed]  [PMC] 
  88. Marson EC, Delevatti RS, Prado AK, Netto N, Kruel LF. Effects of aerobic, resistance, and combined exercise training on insulin resistance markers in overweight or obese children and adolescents: a systematic review and meta-analysis. Prev Med. 2016;93:211-8. [Crossref]  [PubMed] 
  89. Ekelund U, Brage S, Griffin SJ, Wareham NJ; ProActive UK Research Group. Objectively measured moderate-and vigorous-intensity physical activity but not sedentary time predicts insulin resistance in high-risk individuals. Diabetes Care. 2009;32(6):1081-6. [Crossref]  [PubMed]  [PMC] 
  90. Watson RT, Pessin JE. Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res. 2001;56:175-93. [Crossref]  [PubMed] 
  91. Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280(5):465-75. [Crossref]  [PubMed]  [PMC] 
  92. Richter EA, Hargreaves M. Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 2013;93(3):993-1017. [Crossref]  [PubMed] 
  93. Krout D, Roemmich JN, Bundy A, Garcia RA, Yan L, Claycombe-Larson KJ. Paternal exercise protects mouse offspring from high-fat-diet-induced type 2 diabetes risk by increasing skeletal muscle insulin signaling. J Nutr Biochem. 2018;57:35-44. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com